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1. Introduction 
Ischemic heart disease (IHD) remains the major cause of morbidity and mortality in 
developed countries, and has joined infectious diseases in developing countries as a leading 
cause of death (WHO 2008). Decades of research have shown conclusively that a number of 
determinants operating from early childhood onwards, most of them associated with 
lifestyle, are responsible for IHD. 
IHD results when the oxygen demand of the myocardium cannot be met due to an 
inadequate blood supply. The most common cause of myocardial ischemia is atherosclerosis 
of epicardial coronary arteries. The major risk factors for atherosclerosis, and therefore IHD, 
are dyslipidemia (i.e., elevated low-density lipoprotein (LDL) and/or low high-density 
lipoprotein (HDL)), diabetes mellitus, hypertension, cigarette smoking, poor dietary habits, 
and lack of physical activity. These risk factors, particularly when more than one co-exists, 
can progressively damage the vascular endothelium, causing dysregulation of its anti-
inflammatory and anti-thrombotic functions. The associated proliferation of underlying 
fibroblasts and vascular myocytes, together with the accumulation of extracellular matrix 
and lipids, result in the formation of what are known as atherosclerotic plaques that lead to 
a reduction in the luminal diameter. Some of the risk factors for atherosclerosis facilitate the 
development of atherosclerotic plaques, while others sustain or accelerate their formation, 
producing the clinical manifestations of IHD (Parthasarathy 2008, Garelnabi 2010). 
By reducing the lumen of blood vessels, atherosclerosis causes an absolute decrease in 
myocardial perfusion in the basal state and hinders the required increase in perfusion when 
the demand for flow is augmented. As this process progressively worsens, the shear stress 
associated with blood flow through the reduced arterial lumen can cause plaques to erode 
or rupture, exposing the intimal layer to the luminal contents and thereby promoting frank 
thrombosis. Platelet activation, mobilization, and recruitment are central to this process. 
Luminal thrombi can trap red blood cells and acutely reduce coronary blood flow, 
producing a sudden myocardial ischemic event referred to as an acute coronary syndrome 
(ACS) that becomes manifest as either unstable angina or myocardial infarction (MI) if there 
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is complete occlusion without prompt reperfusion. MI may also occur with embolization of 
platelet aggregates and/or atherosclerotic debris from a ruptured plaque. 
Coronary blood flow can also be limited by vascular spasm, as well as by congenital 
abnormalities, such as anomalous origin of the left anterior descending coronary artery from 
the pulmonary artery, which may cause myocardial ischemia and infarction in infancy, but 
is very rare in adults.  
Patients with IHD can be grouped into two broad categories: those having chronic coronary 
artery disease (CAD), who most commonly present with stable angina, and those who 
present with ACSs (i.e., unstable angina and MI). Chronic CAD is most commonly caused 
by slowly progressive coronary artery atherosclerosis, whereby a narrowing of the lumen of 
the coronary arteries limits their ability to adequately increase perfusion in response to an 
increase in demand for oxygen (e.g., during exertion). As the disease progresses in severity, 
perfusion of the myocardium can become compromised even at rest. ACSs, on the other 
hand, are the result of acute vasoocclusive events secondary to thrombosis at sites of erosion 
or rupture of atherosclerotic lesions. 
2. Role of platelets in the etiology and pathophysiology of IHD 
2.1 Structure of platelets 
Blood platelets play an essential role in hemostasis, thrombosis, and coagulation of blood. 
They are engaged in a complex repertoire of biochemical and molecular activities designed 
to prevent hemorrhage. 
On Wright-Giemsa-stained blood smears, platelets appear as small, anucleate, ovoid or 
round cells with a pale grayish blue cytoplasm that contains homogeneously distributed 
purple-red granules. After platelet spreading or aggregation, these dispersed granules 
become concentrated in the middle of the cell. 
When platelet morphology is considered under functional subdivisions rather than purely 
anatomic terms, there are three major structural zones of the platelet, each related to specific 
aspect of platelet function. The peripheral zone is involved primarily in adhesion, the solgel 
zone in contraction, and the organelle zone in secretion. 
The volumes of circulating platelets from a single individual are heterogeneous and exhibit 
a log normal size distribution. Circulating platelets have a volume of 7.06 ± 4.85 µm3 
(femtoliters), a diameter of 3.6  0.7 µm (Mean  SD), and a thickness of 0.9  0.3 µm (Paulus 
et al. 1979, Frojmovic et al. 1976). Platelet size varies from one individual to another, 
although abnormally small or large platelets are present only in certain disease states. By 
scanning electron microscopy, circulating blood platelets appear as flat discs, with smooth 
contours and rare spiny filopodia, with random openings of a channel system, which 
invaginates throughout the platelet and is the conduit by which granule contents exocytose 
after stimulation. Although the platelet is anucleate, transmission electron microscopy 
reveals a cytoplasm packed with a number of different organelles essential to maintenance 
of normal hemostasis. Platelets contain four distinct populations of granules: -granules, 
dense bodies, lysosomes, and microperoxisomes. -granules and dense bodies are 
distinguished morphologically from one another by their electron density as revealed by 
electron microscopy. 
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Phospholipids constitute 80% of the total lipid content of platelets, although smaller 
amounts of neutral lipids and glycolipids are also present. Evidence suggests that these 
phospholipids move to the outer membrane leaflet after platelet activation, thereby 
functioning to promote clot formation. Platelet membrane glycoproteins mediate a wide 
number of adhesive cellular interactions. These glycoproteins function as receptors that can 
receive signals from outside the platelet, facilitating cell-cell interactions; binding of specific 
ligands to these receptors results in distinct platelet responses to the external environment. 
Several other proteins are unique to the platelet, including platelet factor 4 (PF4), low-
affinity PF4, -thromboglobulin (-TG), and the calcium-binding proteins thrombospondin, 
calmodulin, and platelet-derived growth factor (PDGF) (Stenberg et al. 1984).  
2.2 Function and biochemistry of platelets 
In terms of dry weight, platelets are composed of approximately 60% protein, 15% lipid, and 
8% carbohydrate. Platelet minerals include magnesium, calcium, potassium, and zinc. 
Platelets contain substantial amounts of vitamin B12, folic acid, and ascorbic acid (Weiss et 
al. 1968). The concentration of sodium and potassium within the platelet are 39 and 138 
mEq, respectively, a gradient against plasma that is maintained by active ion pumping, 
which derives energy from membrane adenosine triphosphatase of the Ouabain-sensitive, 
Na+/K+-dependent type. Potassium apparently is distributed in two discrete metabolic 
compartments (Cooley and Cohen 1967). 
Non-stimulated platelets maintain a low cytoplasmic Ca2+ concentration, by limiting Ca2+ 
transport from plasma and promoting active efflux of this ion from the cell. Two pools of 
calcium are present in platelets: a rapidly-turning over cytosolic pool that is regulated by 
sodium-calcium antiporter in the plasma membrane, and a more slowly-exchanging pool 
that is regulated by a calcium-magnesium-ATPase and is sequestered in a dense tubular 
system. Platelets are therefore able to transport calcium from the cytosol by moving it 
against a gradient into the extracellular space or by sequestration in the dense tubular 
system (Brass 1984, Enouf et al. 1987). 
There are several similarities between the energy metabolism of platelets and that of skeletal 
muscle. Both involve active glycolysis and the synthesis and use of large amounts of 
glycogen, and in both, the major mediator of intracellular energy use is ATP. Platelets, like 
muscle cells, are metabolically adapted to expend large amounts of energy rapidly during 
aggregation, the release reaction, and clot retraction (Karpatkin et al. 1970). 
The presence of platelets in the hemostatic plugs that form to prevent bleeding suggests that 
platelets have a physiological role in hemostasis. Their presence in thrombi and emboli, 
however, suggests that they may have a pathological role as well. Platelets display certain 
properties that may be relevant to hemostasis and thrombosis. They have the capacity to 
adhere to foreign surfaces, they can be induced to aggregate, and they can synthesize or 
release a number of substances. 
Platelet adhesion 
The only structures with which platelets normally interact are red cells, white cells, and the 
endothelial lining of blood vessel walls. All other surfaces are thus foreign to them, but 
platelets have the ability to adhere to such surfaces. Platelets adhere to subendothelial 
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structures that are exposed when the normal endothelial lining of the blood vessel wall is 
injured, which causes the deposition of a monolayer of platelets on the surface of the injured 
vessel. This is followed by the release of pro-coagulation substances, leading to platelet 
aggregation and formation of a fibrin clot over the adhered layer that results in thrombus 
formation (Heptinstall and Hanley 1985). 
Platelet aggregation 
Platelets circulate as disc-shaped cells, but when they come in contact with exposed 
subendothelium, agonists that activate platelets are exposed, generated, or released. These 
agonists include collagen, which is present in subendothelium; thrombin, which is 
generated on the surface of activated platelets and elsewhere; ADP, which is released from 
damaged red blood cells and secreted from activated platelet-dense granules; circulating 
epinephrine; and arachidonic acid, which is released from lipid stores in platelets and 
metabolized to the potent agonist thromboxane A2 (TXA2). These agonists generally cause 
platelets to change shape such that they form long pseudopodia, followed by platelet 
aggregation. Aggregation requires activation of platelet integrin adhesion receptor GP 
IIb/IIIa so that it can bind fibrinogen or von Willebrand factor (vWF) and link adjacent 
platelets together in an aggregate. Platelet agonists induce signal transduction events in 
platelets that cause the above events, although the signal transduction pathways are not 
completely understood (Leslie et al. 1999). 
Platelet release reaction 
Platelets store ATP, ADP, Ca2+, and serotonin in dense granules as well as adhesive proteins 
such as platelet factor 4, -thromboglobulin, platelet-derived growth factor (PDGF), 
fibrinogen, fibronectin, thrombospondin, and vWF in -granules (Siess 1989). Upon 
activation by agonists, platelets undergo a release reaction, thereby secreting their granular 
contents. The release reaction is associated with the production of TXA2, and the extent of 
the secretion depends on the strength of the agonist. Weak agonists (e.g., ADP and 
epinephrine) require both cyclooxygenase activity and primary aggregation to induce 
secretion that is observed at low Ca2+ concentrations (Smith et al. 1973, Banga et al. 1986). 
Agonists of intermediate strength (e.g., platelet activating factor, PAF) can induce secretion 
in the absence of formation of arachidonic acid metabolism and without primary 
aggregation. Interestingly, when collagen is added at low concentrations to platelet 
suspensions, secretion of ATP occurs before the onset of shape change. This secretion is not 
inhibited by cyclooxygenase blockers, but is sensitive to the extracellular Ca2+ concentration 
and is a direct consequence of platelet binding to collagen (Siess et al. 1983, Malmgren 1986). 
Platelet activation 
Some signaling pathways involved in various platelet activation events are reasonably well 
understood, whereas others are not. Many, but not all platelet agonists activate platelets by 
occupying seven transmembrane-spanning, G protein-coupled receptors. Activation of these 
receptors generally results in activation of phospholipase C (PLC). PLC hydrolyzes 
phosphatidyl-inositol-4,5-bisphosphate (PIP2), generating inositol-1,4,5-triphosphate (IP3) 
and diacylglycerol (DAG). Both IP3 and DAG appear to play important roles in pathways 
leading to various aspects of platelet activation. IP3 is believed to interact with specific 
receptors to induce intracellular Ca2+ release from the dense tubular system, an intracellular 
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Ca2+ storage organelle analogous to the sarcoplasmic reticulum in skeletal muscle. However, 
the exact mechanism by which this response contributes to platelet aggregation is not 
entirely clear because IP3-induced platelet aggregation is also dependent on thromboxane A2 
(TXA2) production and ADP release (Knezevic et al. 1992). DAG interacts directly with 
protein kinase C (PKC) and appears to play a crucial role in the pathways of some agonists, 
leading to the activation of GP IIb/IIIa and fibrinogen binding. Specific inhibitors of PKC 
block fibrinogen binding and platelet aggregation induced by some agonists. Drivers for 
platelet activation include the signaling events that occur downstream of receptors for 
collagen (GP VI and GP Ibα), thrombin (PAR1 and PAR4), adenosine diphosphate (ADP; 
P2Y1 and P2Y12), and thromboxane A2 (TXA2; TP) (Brass 2010). 
Platelets are activated and stimulated to synthesize or release a number of substances, 
namely thrombin, arachidonic acid, PAF, and epinephrine which are of functional 
importance. When platelet ADP is released from platelet-dense granules during platelet 
activation by numerous agonists, secreted ADP potentiates the activating effects of other 
agonists (Hourani and Cusack 1991). ADP causes shape change, granular secretion, and 
aggregation. However, unlike strong agonists such as thrombin and collagen, ADP induces 
secretion usually only in conjunction with platelet aggregation. Strong agonists generally 
stimulate phosphoinositide hydrolysis, increase cytosolic free Ca2+, and induce TXA2 
formation. 
Platelet receptors and MicroRNA signaling 
Platelet receptors are known to interact with external stimuli in the main blood stream 
leading to the regulation of platelet activation. Platelet adhesion receptors are the key 
initiators of platelet activation at sites of vascular injury, where platelets become exposed to 
adhesive proteins in the matrix, or on endothelial cells. Despite significant differences in 
their functions and signaling pathways, several major platelet adhesion receptors share 
many similarities in their signal transduction mechanisms (Li et al. 2010). The most studied 
platelet receptor is platelet integrin GP IIb/IIIa, which is reported to play an essential role in 
thrombus formation through interactions with adhesive ligands and has emerged as a 
primary target for the development of anti-thrombotic agents (Hagemeyer and Peter 2010). 
Successful blockade of this ligand binding has validated GP IIb/IIIa as a therapeutic target 
in cardiovascular medicine.  
MicroRNAs (MiRs) molecules are a novel class of endogenous, small, noncoding RNAs that 
regulate gene expression via degradation, translational inhibition, or translational activation 
of their target messenger RNAs (Pan et al. 2010, O’Sullivan et al., 2011). Bioinformatics 
analysis predicts that each MiR can regulate hundreds of targets, suggesting that they play 
an essential role in almost every physiological and pathological pathway. Functionally, an 
individual MiR is important as a transcription factor because it is able to regulate the 
expression of its multiple target genes. MiRs are short (~20 nucleotides long), single-
stranded RNAs initially transcribed by either RNA polymerase II or RNA polymerase III, as 
a long primary MiR transcript (pre-MiR). It is then cleaved in the nucleus by the 
microprocessor complex, Drosha-DGCR8, resulting in a precursor hairpin (pre-miRNA) 
ranging in length from 60 to 110 nucleotides. The pre-MiRNA is exported from the nucleus 
to the cytoplasm by exportin 5-Ran-GTP. In the cytoplasm, Dicer, a member of the RNase III 
family, in complex with TRBP, cleaves the pre-MiR hairpin to a 22 base pair MiR duplex. 
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The mature MiR is incorporated with argonaute (Ago2) proteins into the RNA-induced 
silencing complex (RISC), where MiR guides the complex to partial complementary binding 
sites located in the 3’ untranslated region (UTR) of target mRNAs to suppress gene 
expression. MiRs are able to directly regulate at least 30% of genes in a cell. In addition, 
other genes may also be regulated indirectly by MiRs. Therefore, MiRs are pivotal regulators 
in normal development, physiology, and pathology. Recent studies have identified a 
number of MiRs highly expressed in the vasculature and their expression is dysregulated in 
diseased vessels (Jamaluddin et al. 2011, Haver et al. 2010, Bonauer et al. 2010, Wierda et al. 
2010, Urbich et al. 2008, Fang et al. 2010, Leeper et al. 2011). MiRs are also found to be critical 
modulators of cell differentiation, contraction, migration, proliferation, and apoptosis. 
Accordingly, MiRs have emerged as therapeutic targets in disease. 
Platelets are also reported to have microRNA population that may regulate its activity. It is 
well known that platelets have mRNA and mRNA splicing machinery, and translate mRNA 
into proteins relevant to hemostasis and inflammation (Edelstein and Bray 2011). In silicon 
analysis work from Edelstein and Bray indicates that each platelet MiR targets an average of 
307 distinct mRNAs, concluding in their review that platelet MiRs have ample opportunity 
to regulate platelet function. 
2.3 Role of inflammation and oxidative stress in platelet activation 
Involvement of inflammation in cardiovascular disease is well defined. Circulating platelets 
are affected by this metabolic disruption and by inflammatory mediators synthesized 
and/or released on contact with inflammatory signals. Platelets are known to play a major 
role in this process and have been identified as targets and players in inflammation-induced 
cardiovascular disease (Weksler 1983, Nurden 2011). It has been explicitly established that 
free radicals can cause metabolic disturbances and cell injury in a variety of ways, including 
lipid peroxidation, hydroxyl radical-induced modification of proteins and nucleic acids, 
changes in enzyme activity, and carbohydrate damage. Oxidative modification of lipids can 
be induced in vitro by a wide array of pro-oxidant agents and occurs in vivo during 
atherosclerosis and several other disease conditions (Parthasarathy et al. 2008). Alterations 
in the superoxide and glutathione oxidation-reduction system may lead to depleted 
antioxidant capacity and may result in oxidative stress. Previous studies have suggested 
that platelets and vascular endothelial cells could be the central target as well as the origin 
of oxygen free radicals or its metabolites (Dousset et al. 1983). Measuring the end products 
of lipid peroxidation is one of the most widely accepted assays for oxidative damage. These 
aldehydic secondary products of lipid peroxidation are generally accepted markers of 
oxidative stress. 
Several studies suggest that the basal release of NO by the endothelium contributes to 
regulation of the vascular tone (Antoniades et al. 2008), blood flow, and blood pressure. NO 
inhibits platelet aggregation and adhesion to vascular endothelium. In addition, NO inhibits 
leukocyte adhesion to endothelium (Petidis et al. 2008). Alteration of cellular calcium 
homeostasis is also a critical event in ischemic heart injury. NO released by endothelium or 
synthesized by platelets participates in the regulation of Ca2+ signaling. Elevation of cGMP 
as a result of the activation of guanylate cyclase by NO stimulates a number of mechanisms 
that actively decrease calcium levels within the cell (Joseph et al. 1996). Although the NO-
cGMP signaling system has been immensely investigated, sparse data is available pertaining 
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to the role of platelet NO activity in coronary artery (CAD). We and others have studied the 
NO-cGMP system in patients with CAD, particularly the role of oxidative stress and NO-
mediated platelet response in IHD (Garelnabi et al. 2010, Ikeda et al. 2000, Garelnabi et al. 
2011). These studies have clearly indicated that lipid peroxidation is augmented in patients 
with ischemic heart disease. The increased oxidative stress seen in these patients was 
accompanied by platelet activation and impaired antioxidant enzymes activity. On the other 
hand, platelet aggregation, NO, cGMP, NO synthase activity, plasma NO, and ionized Ca2+ 
was profoundly increased in CAD. The increases in NO-cGMP components may have 
resulted as a compensatory response to ameliorate platelet activity and increased Ca2+ levels 
in CAD patients. Another interesting modulator of platelet activity is the recent description 
of platelet-derived microparticles (PMP) which are known as a heterogeneous population of 
vesicles (<1 mm) generated from the plasma membrane upon platelet activation by various 
stimuli. These PMPs have been shown to not only stimulate the response of platelets, but 
have also been reported to mediate the intercellular transfer of bioactive molecules such as 
lipids, surface receptors, and even enzymes (Siljander 2010). 
3. Classes and mechanism of action of antiplatelet drugs 
The main goals of pharmacological intervention in patients with IHD are to reduce the 
occurrence of anginal attacks by minimizing the rise in blood pressure and heart rate 
associated with physical activity so that patients can go about their daily activities without 
ischemic episodes. Given the prominent role that thrombosis plays in IHD, antiplatelet 
therapy is one of the most important modalities used in its treatment. 
Antithrombotic drugs used for prevention and treatment of thrombosis include: (1) 
antiplatelet drugs, (2) anticoagulants, and (3) fibrinolytic agents. Given the predominance of 
platelets in arterial thrombi, which are the major source of IHD, the treatment and inhibition 
of arterial thrombosis focus mainly on antiplatelet agents, although anticoagulants and 
fibrinolytic drugs are often included in the acute setting. 
Under normal conditions, the actions of vascular endothelial cells maintain platelets in the 
bloodstream in an inactive state, largely by their production of nitric oxide (NO) and 
prostacyclin, but also by their surface expression of adenosine diphosphatase (ADPase), which 
breaks down ADP released via degranulation of activated platelets. With the occurrence of 
injury to the vascular endothelium, production of these substances is compromised and certain 
components of the subendothelial matrix are exposed (e.g., collagen, von Willebrand factor 
(vWF), and fibronectin) to which platelets adhere via receptors constitutively expressed on 
their surface (e.g., GP IIb/IIIa). As discussed above, adhered platelets undergo a 
morphological change and then release the contents of their dense granules (e.g., ADP) and 
synthesize and release thromboxane A2 (TXA2), both of which serve to recruit and activate 
surrounding circulating platelets to the site of vascular injury. 
Disruption of the vascular wall also exposes underlying cells and matrix that express pro-
thrombotic factors to the circulation, which triggers the coagulation cascade. Activated 
platelets enhance coagulation by binding clotting factors and supporting the assembly of 
activation complexes that increase thrombin generation, which in addition to converting 
fibrinogen to fibrin, also acts as a potent platelet agonist and recruits more platelets to the 
site of vascular injury. 
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The most abundant receptor on the surface of platelets is GP IIb/IIIa, which undergoes a 
conformational change upon platelet activation that allows it to bind fibrinogen. Divalent 
fibrinogen molecules link adjacent platelets together to form aggregates, which are meshed 
together via fibrin strands generated via the action of thrombin to form a lattice composed 
of platelets plus fibrin. Antiplatelet drugs target various steps in this process. The most 
commonly used drugs include cyclooxygenase inhibitors, among which aspirin is the most 
common, thienopyridines and functionally related drugs, phosphodiesterase inhibitors, 
adenosine reuptake inhibitors, and GP IIb/IIIa antagonists, all of which are discussed 
below. 
3.1 Cyclooxygenase inhibitors 
The cyclooxygenases (COXs) are a family of isoenzymes responsible for the biosynthesis of 
various important and potent pro-inflammatory and pro-thrombotic mediators called 
eicosanoids, which include prostaglandins, leukotrienes, and thromboxanes. Non-steroidal 
anti-inflammatory drugs (NSAIDs), like aspirin and ibuprofen, exert their effects through 
inhibition of COX, and as such they relieve the symptoms of inflammation (e.g., pain, 
swelling). 
COX converts arachidonic acid (AA, an ω-6 polyunsaturated fatty acid (PUFA)) to 
prostaglandin H2 (PGH2), the parent of the eicosanoids, which can then be converted to the 
other compounds via further enzymatic action that involves radical chemistry and the 
consumption of molecular oxygen. To date, three distinct COX isoenzymes have been 
identified: COX-1, COX-2, and COX-3. COX-1 and COX-3 are products of alternative 
splicing of the same gene, so COX-3 is referred to by some as COX-1b or COX-1 variant 
(COX-1v). Different tissues express varying levels of the different COXs, and although the 
isoenzymes basically catalyze the same transformations, selective inhibition can produce a 
different side-effect profile. COX-1 is nearly ubiquitous among mammalian cells, but COX-2 
is undetectable in most normal tissues and is inducible in macrophages upon their 
activation, as well in endothelial cells at sites of inflammation, where it serves to produce 
prostacyclin, a potent vasodilator and inhibitor of platelet aggregation. COX-2 is also 
upregulated in various types of cancers, so it is believed to play a role in oncogenesis. 
Both COX-1 and -2 also oxygenate two other essential fatty acids – dihomo-γ-linolenic acid 
(DGLA, ω-6) and eicosapentaenoic acid (EPA, ω-3) – to give eicosanoids with less potent 
pro-inflammatory properties than those derived from AA. Both DGLA and EPA 
competitively inhibit oxidation of AA by the COXs, which is believed to be the major 
mechanism by which dietary sources of DGLA and EPA (e.g., fish oil) can reduce 
inflammation. 
The traditional COX inhibitors are not selective for any particular COX, resulting in 
widespread inhibition of eicosanoid synthesis that ultimately reduces inflammation, as well 
as providing antipyretic, antithrombotic, and analgesic effects. However, inhibition of the 
synthesis of gastroprotective prostaglandins can cause gastric irritation and increases the 
risk of development of peptic ulcer disease. 
The development of selective COX-2 inhibitors was originally aimed at blocking the 
production of pro-inflammatory prostaglandins while minimizing any effects on platelet 
and gastric function. Selective inhibition of COX-2 has been accomplished with the 
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“coxibs”, which differ in their selectivity for COX-2 relative to COX-1 by selectively 
binding to a hydrophobic side-pocket on the COX-2 enzyme where a valine takes the 
place of what is an isoleucine on COX-1, allowing access to an otherwise sterically 
hindered site that causes inhibition of the enzyme’s function. Since COX-2 is largely 
expressed selectively in inflamed tissue, there is much less gastric irritation and risk of 
peptic ulceration associated with COX-2 inhibitors. However, the selectivity of COX-2 
causes an imbalance between thromboxane and prostacyclin, resulting in an increased 
risk of thrombosis, MI, and stroke. Thus, by blocking prostacyclin synthesis without 
concomitant inhibition of thromboxane A2 (TXA2) production, highly selective inhibitors 
of COX-2 increase the risk of cardiovascular events. These effects seemed most notable 
with rofecoxib (Vioxx®) and valdecoxib (Bextra®), which were removed from the market 
in 2004 and 2005, respectively. Other COX-2 selective NSAIDs, such as celecoxib 
(Celebrex®), and etoricoxib (Arcoxia®), are still on the market as they continue to be 
investigated for these adverse effects. Even with short-term use, COX-2 inhibitors have 
been found to increase the risk of atherothrombosis, most notably manifested as a 2-to-5-
fold increased risk of myocardial infarction. Furthermore, high-dose regimens of some 
traditional NSAIDs such as diclofenac and ibuprofen are associated with a similar 
increase in risk of vascular events. Thus, although NSAIDs, particularly COX-2 inhibitors, 
have demonstrated benefits, the risks associated with their use should be seriously 
considered when prescribing them to a patient having risk factors and/or a personal or 
family history of IHD. 
3.1.1 Aspirin 
 
 
Aspirin (acetylsalicylic acid, ASA), is the oldest and most widely used antiplatelet drug due 
to its low cost, wide availability, and proven effectiveness. It is a salicylate drug whose 
mechanism of action serves as the model of most antiplatelet therapeutic strategies. 
Mechanism of action 
Aspirin, a non-selective COX inhibitor, is one of the most commonly used drugs in IHD that 
can reduce the development of thrombosis associated with the rupture of atheromatous 
plaques. Aspirin interferes with the activation of platelets by irreversibly inhibiting COX, 
thereby interfering with the biosynthetic pathway of thromboxanes. Unlike other NSAIDs, 
whose antiplatelet action is transient (i.e., in the order of hours), aspirin irreversibly 
acetylates COX-1 in platelets, thereby inhibiting the biosynthesis of thromboxane A2 (TXA2) 
and in that manner producing a long-lived antithrombotic effect (i.e., days, until new 
platelets are produced by the bone marrow). At higher doses (e.g., 1 g/d), however, aspirin 
also inhibits COX-2, which can ultimately produce a prothrombotic effect by inhibiting the 
synthesis of prostacyclin in endothelial cells. 
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Indications, dosage, and side effects 
Aspirin is widely used for the primary prevention of ischemic events in patients at risk, as well 
as secondary prevention of cardiovascular events in patients with IHD and cerebrovascular 
and peripheral vascular disease. Aspirin is usually administered once a day at a dose between 
75-325 mg, with 75-100 mg being recommended for most indications. When fast platelet 
inhibition is needed, a dose of at least 160 mg should be given orally. Higher doses of aspirin 
have not been shown to be more effective than lower doses, and in fact, reduced efficacy has 
been reported with higher doses. As discussed above, very high doses of aspirin (i.e., 1 g/d) 
can have a paradoxical prothrombotic effect due to the inhibition of COX-2. 
Long-term daily oral enteric-coated aspirin has been demonstrated to reduce (1) the 
incidence of anginal episodes in patients with chronic stable angina, as well as in survivors 
of unstable angina and myocardial infarction (MI), and (2) the risk of recurrent infarction, 
stroke, or cardiovascular mortality by 25% following an MI compared with placebo. It has 
also been established that low doses of aspirin may be given immediately after an MI to 
reduce the risk of another MI or of the death of the myocardium. 
Aspirin is equally effective in men and women, although in men it mainly reduces the risk 
of MI, while in women it lowers the risk of stroke. Although aspirin also raises the risk of 
hemorrhagic stroke and other major bleeds, these events are rare, and are by far outweighed 
by aspirin’s positive effects. 
The most common side effects of aspirin use are gastrointestinal, ranging from simple stomach 
upset, to erosive gastritis, to peptic ulcers with bleeding and perforation, all of which are dose-
dependent. For these reasons, aspirin should never be administered to individuals with a 
history of gastrointestinal bleeding or severe stomach upset. Although the use of enteric-
coated or buffered aspirin may relieve some of these symptoms, they do not eliminate the risk 
of gastrointestinal complications due to the inhibition of gastroprotective prostaglandins as 
part of the actions of aspirin. The overall risk of major bleeding with aspirin is low, however, 
estimated at 1-3% per year, but is increased when aspirin is given in conjunction with 
anticoagulants (e.g., warfarin). In these situations, a lower dose of aspirin should be given (e.g., 
75-100 mg/d). In patients with a documented history of peptic ulcer disease caused by 
Helicobacter pylori infection, treatment of the infection and administration of a proton pump 
inhibitor (PPI) may reduce the risk of aspirin-induced gastrointestinal bleeding. Aspirin 
should also never be given to individuals with a history of allergic responses to salicylates, 
particularly those associated with bronchospasm. 
3.2 Thienopyridines 
A second class of antiplatelet drugs commonly used in IHD is the thienopyridines. These 
structurally related drugs have similar benefits as aspirin in patients with stable chronic 
IHD and may be used instead of aspirin when aspirin is contraindicated. The 
thienopyridines include clopidogrel (Plavix®), ticlopidine (Ticlid®), and prasugrel (Effient®). 
A structurally unrelated but functionally similar drug is ticagrelor (Brilinta®). 
Mechanism of action 
The thienopyridines are prodrugs that must first be metabolized by the hepatic cytochrome 
P450 enzyme system before they can exert any biological activity, so their onset of action can 
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be delayed for several days. They interfere with the aggregation of platelets by 
competitively and irreversibly inhibiting the adenosine diphosphate (ADP) chemoreceptor 
P2Y12 on the surface of platelets, which is crucial for the conformational change that 
activates GP IIb/IIIa and ultimately leads to platelet aggregation and cross-linking by fibrin. 
3.2.1 Clopidogrel (Plavix
®
) 
 
Clopidogrel is an oral thienopyridine marketed under the trade name Plavix by Bristol-
Myers Squibb and Sanofi-Aventis as 75 mg oral tablets. 
Indications, dosage, and side effects 
Clopidogrel is indicated for the prevention of vascular ischemic events in patients with 
symptomatic atherosclerosis, acute coronary syndromes, and MI. When compared with 
aspirin in patients with recent ischemic stroke, MI, or peripheral arterial disease, clopidogrel 
further reduced the risk of cardiovascular death, MI, and stroke by nearly 10%. Thus, although 
clopidogrel is actually more effective than aspirin in reducing morbidity and mortality of IHD, 
it is also considerably more expensive and not as readily available. It is also used, together 
with aspirin, for the prevention of thrombotic events after placement of intracoronary stents, 
or as an alternative to aspirin in patients who have a contraindication for aspirin. 
Combination therapy consisting of aspirin and clopidogrel has been shown to reduce 
morbidity and mortality in patients with angina and it also reduces the risk of thrombosis in 
patients who have undergone coronary artery stenting (the risk of gastrointestinal bleeding in 
these patients can be reduced by also prescribing a PPI while on this combination therapy). 
The combination therapy of clopidogrel and aspirin capitalizes on the capacity of these drugs 
to inhibit complementary pathways of platelet activation and is associated with a highly 
statistically significant 20% relative risk reduction when comparing each drug alone. 
In patients with a history of acute coronary syndrome, it is standard medical practice to 
administer aspirin indefinitely, and it is recommended that combination therapy with 
clopidogrel be given for 1-3 months after the implantation of a bare metal stent. With the use 
of drug-eluting stents, which deliver antiproliferative drugs locally (e.g., rapamycin or 
paclitaxel), combination therapy should continue for at least one year because these drugs 
are associated with delayed endothelial healing that prolongs the window during which 
there is an increased risk for thrombosis around the area where the stent was placed. 
Although aspirin and clopidogrel may help prevent coronary thrombosis associated with 
stenting, there is no evidence that these drugs reduce the occurrence of re-stenosis. 
However, the use of drug-eluting stents can reduce re-stenosis to near zero within the stent 
itself and less than 10% at its edges. 
There is little evidence of additional benefit of adding clopidogrel to the routine regimen of 
aspirin in patients with chronic stable IHD that have not undergone stenting. However, 
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“aspirin resistance” has been noted in up to 10% of patients, more frequently in patients 
treated with lower doses of aspirin. In these cases, the use of higher doses of aspirin and/or 
combination therapy with clopidogrel should be considered. Although the routine 
management of patients with IHD is medical, many patients show greater improvement 
after undergoing interventional coronary revascularization. These invasive procedures 
should not take the place of the required ongoing modification of risk factors and medical 
therapy but rather should be performed in combination with them. 
Combination therapy of aspirin and clopidogrel increases the risk of major bleeding to 
about 2% per year, a risk that will exist even if the daily dose of aspirin is reduced to 100 
mg. Thus, the combination of clopidogrel and aspirin should only be used when there is a 
clear benefit. For example, combination therapy has not been shown to reduce the risk of 
acute ischemic stroke relative to clopidogrel alone or to reduce the risk of primary 
cardiovascular events when compared to aspirin alone. 
As mentioned above, the onset of action of clopidogrel is slow, so even though platelet 
inhibition can be seen within a few hours after a single oral dose of the drug, a loading-dose 
between 300-600 mg is commonly given when prompt inhibition of the ADP receptors is 
desired, which is continued as a once daily oral dose of 75 mg for maintenance. 
The documented adverse effects of clopidogrel include bleeding, severe neutropenia, and 
thrombotic thrombocytopenic purpura (TTP). Patients with a history of resolved aspirin-
related peptic ulcers who received aspirin plus a PPI (e.g., esomeprazole) were shown to 
have a lower incidence of recurrence of peptic bleeding when compared to patients 
receiving clopidogrel instead. Another study suggested that prophylaxis with PPIs when 
undergoing treatment with clopidogrel following an acute coronary syndrome (ACS, i.e., 
unstable angina or MI) may increase the incidence of adverse cardiac events, perhaps as a 
result of the inhibition of the cytochrome P450 variant CYP2C19, which is required for the 
conversion of clopidogrel to its pharmacologically active form. However, even after some 
government health agencies issued a statement on a potential drug interaction between 
clopidogrel and PPIs, people within the cardiology community manifested concerns 
regarding the possible existence of flaws in the studies that served as the basis for these 
conclusions and subsequent warnings, putting into question the veracity of an adverse drug 
interaction between clopidogrel and PPIs. 
Clopidogrel, was issued a black box warning from the FDA on March 12, 2010 because it is 
estimated that 2-14% of the US population have low levels of the CYP2C19 liver enzyme 
needed to activate clopidogrel and, therefore, may not get the full effect from the drug. 
However, there are tests available to predict if a patient will be susceptible to this reduced 
pharmacological effect. 
3.2.2 Ticlopidine (Ticlid
®
) 
 
 
Ticlopidine is an oral thienopyridine marketed under the trade name Ticlid by Roche 
Pharmaceuticals as 250 mg oral tablets.  
www.intechopen.com
 
Platelet Activation in Ischemic Heart Disease: Role of Modulators and New Therapies 
 
147 
Indications, dosage, and side effects 
Ticlopidine is typically administered as an oral twice-daily dose of 250 mg. Like aspirin, 
ticlopidine is more effective than placebo at reducing the risk of cardiovascular death, MI, 
and stroke in patients with atherosclerotic disease, but due to its delayed onset of action, 
ticlopidine is not recommended for patients with acute MI. Ticlopidine has been routinely 
used in addition to aspirin after coronary artery stenting, and as a substitute for aspirin in 
patients with a contraindication to aspirin. However, because ticlopidine is less potent than 
clopidogrel and is associated with greater risk of hematologic disorders (e.g., neutropenia, 
TTP, thrombocytopenia, aplastic anemia), it has largely been replaced by clopidogrel. Due to 
the known hematologic side effects, which usually become manifest within the first few 
months of beginning therapy, frequent blood counts must be carefully performed when 
taking ticlopidine. As with clopidogrel, it is contraindicated in patients having 
hypersensitivity reactions to thienopyridines, as well as bleeding disorders, active bleeding, 
and liver disease. 
3.2.3 Prasugrel (Effient
®
) 
 
 
Prasugrel is an oral thienopyridine marketed under the trade names Effient, Efient, Apagrel, 
and Prasita. It was developed by Daiichi Sankyo Co. and is currently marketed in the United 
States in cooperation with Eli Lilly and Co. as 5 mg and 10 mg oral tablets. 
Indications, dosage, and side effects 
Prasugrel was approved for patients with acute coronary syndrome who will be undergoing 
a percutaneous coronary intervention (PCI) to reduce the occurrence of cardiovascular 
thrombotic events. Prasugrel is faster than clopidogrel at inhibiting ADP-induced platelet 
aggregation and does so to a greater extent than both normal and higher doses of 
clopidogrel in healthy individuals, as well as in patients with coronary artery disease, 
including those undergoing PCI. Unlike clopidogrel, prasugrel has not been shown to 
produce a lesser effect in patients who have a low level of hepatic CYP2C19 enzyme. 
Prasugrel should be administered as a single 60 mg oral loading dose and then continued at 
a dose of 10 mg orally once daily. Patients should also take aspirin (75-325 mg) per day. 
A study published in the New England Journal of Medicine that compared prasugrel with 
clopidogrel in patients with acute coronary syndromes, both in combination with aspirin, 
found that prasugrel was a more potent anti-platelet agent, demonstrating a 1.2-fold 
reduction in the combined rate of cardiovascular mortality, nonfatal myocardial infarction, 
and nonfatal stroke. However, prasugrel was associated with a 1.6-fold rate of serious 
bleedings and 4-fold rate of fatal bleedings, even though overall mortality did not differ 
between the two patient groups. 
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3.2.4 Ticagrelor (Brilinta
®
) 
 
Ticagrelor is an oral cyclopentyltriazolopyrimidine (CPTP) agent marketed under the trade 
names Brilinta, Brilique, and Possia. The drug was approved for use in the European Union 
on December 3, 2010 and by the US Food and Drug Administration on July 20, 2011, being 
marketed in the United States by AstraZeneca as 90 mg oral tablets. 
In contrast to the other antiplatelet drugs clopidogrel, ticlopidine, and prasugrel, ticagrelor 
is a reversible allosteric inhibitor that does not require hepatic activation, making it a better 
choice for patients with hepatic insufficiency or those carrying low levels or genetic variants 
of the CYP2C19. Due to its reversible mode of action, ticagrelor is both faster and shorter 
acting than clopirogrel, making it a easier to discontinue (e.g., surgery, hypersensitivity), but 
typically requiring more frequent dosing, which can present an issue with compliance. 
In a study by AstraZeneca, ticagrelor was associated with ~2% lower mortality rate than 
clopidogrel in patients with ACS and it was found that taking ticagrelor displayed a lower 
mortality rate from vascular causes, heart attack, or stroke. However, patients taking 
ticagrelor was associated with 1.5% higher propensity of non-lethal bleeding. 
Indications, dosage, and side effects 
Treatment with ticagrelor should be initiated as an oral loading dose of 180 mg, and then 
continued at 90 mg orally twice daily. Patients should also take aspirin (75-100 mg) daily. 
Ticagrelor is indicated for the prevention of thrombotic events in patients with ACS or MI, 
in combination with aspirin unless the latter is contraindicated. Compared with clopidogrel, 
ticagrelor significantly reduces the mortality rate in patients with ACS. The drug is 
contraindicated in patients with hepatic insufficiency and a history of pathological bleeding. 
It also should not be given in combination with other drugs that affect the CYP3A4 liver 
enzyme, since the drug is metabolized by CYP3A4 and is mainly excreted via bile and feces.  
The most common side effects of ticagrelor are dyspnea as well as bleeding (e.g., 
gastrointestinal, nasal, subcutaneous/dermal). To date, less than 1% of patients taking 
ticagrelor have reported allergic reactions. 
Inhibitors of hepatic CYP3A4 enzyme (e.g., ketoconazole and (?) grapefruit juice), increase 
blood plasma levels of ticagrelor and can therefore cause bleeding and other adverse effects. 
Conversely, activators of hepatic CYP3A4 (e.g., rifampicin and (?) St. John’s wort), can 
reduce the effectiveness of ticagrelor. Furthermore, drugs that are also metabolized by 
CYP3A4 (e.g., simvastatin), will display higher plasma levels, which can result in an 
increase of the side effects of these drugs when combined with ticagrelor. 
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3.2.5 Thienopyridine resistance 
There is variability among different individuals in the ability of the thienopyridines to 
inhibit ADP-induced platelet aggregation. To a certain extent this variability reflects genetic 
polymorphisms in the CYP isoenzymes associated with the metabolic activation of these 
drugs. For example, individuals carrying the CYP2C19*2 allele have been shown to display 
a lower responsiveness to clopidogrel, in a similar fashion as those having a lower activity of 
hepatic CYP3A4. These observations have resulted in the proposal that genetic testing may 
lead to the identification of individuals that may experience resistance to the effects of 
thienopyridines. 
3.3 Phosphodiesterase inhibitors and adenosine reuptake inhibitors 
As the name implies, phosphodiesterase inhibitors interfere with the function of the enzyme 
phosphodiesterase, which breaks down the intracellular second messenger cyclic adenosine 
monophosphate (cAMP). This results in increased levels of cAMP, ultimately leading to the 
inhibition of platelet activation and vasodilation. 
3.3.1 Cilostazol (Pletal
®
) 
 
 
Cilostazol is an oral phosphodiesterase inhibitor marketed under the trade name Pletal. The 
drug is marketed in the United States by Otsuka Pharmaceutical Co. as 50 and 100 mg oral 
tablets. Cilostazol is not used in the treatment of ischemic heart disease but rather in the 
relief of intermittent claudication in patients with peripheral vascular disease. 
3.3.2 Dipyridamole (Persantine
®
 and Aggrenox
®
 (in combination with aspirin)) 
 
 
Dypyridamole is an oral phosphodiesterase inhibitor marketed as a single drug under the 
trade name Persantine, and as an extended-release combination with low-dose aspirin 
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under the name Aggrenox. Persantine drug is marketed in the United States by Boehringer 
Ingelheim Pharmaceuticals, Inc. as 25, 50, and 75 mg oral tablets, while Aggrenox contains 
200 mg of extended-release dipyridamole and 25 mg of aspirin. 
Dypiridamole also inhibits the reuptake of adenosine by platelets, red blood cells, and 
vascular endothelial cells, as well as the enzyme adenosine deaminase, which metabolizes 
adenosine into inosine. Both of these effects increase the extracellular concentration of 
adenosine, which causes smooth muscle relaxation and is, at least in part, responsible for the 
vasodilatory effects of dipyridamole. Persantine causes vasodilation when given at high 
doses over a short time and it inhibits thrombosis when given long term by also acting as a 
thromboxane synthase inhibitor.  
Indications, dosage, and side effects 
The recommended dose of dipyridamole is 75-100 mg four times daily as an adjunct to 
warfarin therapy. Dipyridamole is a relatively weak antiplatelet agent on its own and thus is 
not used for the treatment of IHD. However, dipyridamole has been shown to increase 
myocardial perfusion and left ventricular function in patients with ischemic 
cardiomyopathy. In combination with low-dose aspirin (i.e., Aggrenox) it is used for 
prevention of stroke in patients with a history of transient ischemic attacks given as a twice-
daily dose. 
When given by intravenous infusion over 3-5 minutes, dipyridamole is associated with a 
rapid increase in the local concentration of adenosine in the coronary circulation, which has 
a vasodilatory effect. However, this vasodilation largely occurs in healthy coronary arteries, 
while those arteries that are stenosed remain so. This results in an imbalance of coronary 
perfusion that can become clinically manifest by symptoms of chest pain as well as 
electrocardiographic signs of ischemia. 
Dipyridamole combined with aspirin reduces the risk of stroke by 22.1% compared with 
aspirin and by 24.4% compared with dipyridamole alone in patients with a history of 
cerebrovascular disease (i.e., TIA and/or stroke). With regard to secondary prevention in 
patients with a history of ischemic stroke, combination therapy resulted in 13% of patients 
having vascular death, stroke, or MI as opposed to 16% of those treated with aspirin alone. 
Based on all this data, Aggrenox is often used for stroke prevention. However, because it 
has vasodilatory effects, combination therapy of dipyridamole with aspirin (i.e., Aggrenox) 
should not be used for the prevention of stroke in patients with symptomatic coronary 
artery disease. A triple therapy of aspirin, clopidogrel, and dipyridamole has been 
investigated, but an increase in adverse bleeding events was observed with this 
combination. 
The major side effects documented with the use of dipyridamole are gastrointestinal, 
headache, facial flushing, dizziness, and hypotension, which often disappear with continued 
use of the drug. 
3.4 GP IIb/IIIa receptor antagonists 
As a member of the integrin family of adhesion receptors, GP IIb/IIIa is found on the 
surface of platelets and megakaryocytes. With about 80,000 copies, GP IIb/IIIa is the most 
abundant receptor on platelets. GP IIb/IIIa consists of a non-covalently linked heterodimer 
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that is inactive on resting platelets. When platelets are activated, a signal transduction 
pathway triggers a conformational change on the receptor that leads to its activation. 
Activated GP IIb/IIIa can bind other adhesion molecules (e.g., fibrinogen, vWF) under 
conditions of high shear stress. Binding is mediated by an Arg-Gly-Asp (RGD) sequence 
found on both fibrinogen and vWF, and by a Lys-Gly-Asp (KGD) sequence located within a 
unique dodecapeptide domain on fibrinogen. Once GP IIb/IIIa is bound to fibrinogen 
and/or vWF, adjacent platelets can be bridged together and lead to platelet aggregation. 
Abciximab, eptifibatide, and tirofiban all target the GP IIb/IIIa receptor, but as described 
below, they are structurally and pharmacologically distinct. Abciximab has a long half-life 
and can be detected on the surface of platelets for a couple of weeks, while eptifibatide and 
tirofiban have shorter half-lives. 
All of the GP IIb/IIIa antagonists are administered by intravenous (IV) infusion following 
an IV bolus. The dosage of eptifibatide and tirofiban must be reduced in patients with renal 
insufficiency since they are cleared by the kidneys. 
The most serious complications of GP IIb/IIIa inhibitors are bleeding and 
thrombocytopenia, which is immunoglobulin-mediated as a result of antibodies directed 
against neoantigens on GP IIb/IIIa that form upon binding of the drug. 
3.4.1 Abciximab (ReoPro
®
) 
Abciximab is manufactured by Centocor and distributed by Eli Lilly. As with all of the GP 
IIb/IIIa antagonists, it is administered by intravenous (IV) infusion. It is a humanized 
murine monoclonal immunoblogulin Fab fragment directed against the activated form of 
GP IIb/IIIa that binds to the activated receptor with high affinity and blocks the binding of 
adhesion molecules.  
Indications, dosage, and side effects 
Abciximab is used in the setting of percutaneous coronary interventions (e.g., angioplasty, 
with or without stenting) to prevent platelet aggregation and thrombosis. It is administered 
as an IV bolus at 0.25 mg/kg, 10 to 60 min before PCI followed by continuous infusion of 
0.125 µg/kg/min (to a max of 10 µg/min) for 12 h. Its use is associated with a reduction in 
both the incidence of ischemic complications, as well as the necessity for repeated 
interventional procedures within the first thirty days. Patients with diabetes and chronic 
renal insufficiency can be given abciximab, but its use is contraindicated in patients who 
shall be undergoing an emergent surgical procedure (e.g., coronary artery bypass grafting), 
since bleeding time may remain elevated for up to 12 hours. 
Abciximab has a relatively short half-life (i.e., ~10-30 min), but its pharmacological effects on 
platelet function persist for up to 48 hours after cessation of IV infusion, followed by a low 
degree of GP IIb/IIIa receptor blockade that can continue for up to two weeks. 
Many of the side effects of abciximab are due to its anti-platelet effects, including an 
increased risk of bleeding (e.g., gastrointestinal hemorrhage). Thrombocytopenia is a rare 
but known serious risk that occurs in up to 5% of individuals receiving the drug, which can 
be severe in ~1% of these patients. Abciximab-induced thrombocytopenia can typically be 
treated with transfusion of platelets. Abciximab induced thrombocytopenia can last for 
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seven days after initial drug administration. Transfusing platelets is the only known 
treatment and may have limited effectiveness as the drug may also bind to the new platelets. 
Platelet counts, which should average 250,000-400,000, can effectively drop to zero. 
In addition to targeting the GP IIb/IIIa receptor, abciximab also inhibits the closely related 
v3 receptor, which binds vitronectin, and M2, a leukocyte integrin. In contrast, eptifibatide 
and tirofiban are specific for GP IIb/IIIa. Inhibition of v3 and M2 may impart abciximab 
with anti-inflammatory and/or antiproliferative properties that extend beyond the 
inhibition of platelets. 
3.4.2 Tirofiban (Aggrastat
®
) 
 
 
 
Tirofiban is marketed the United States by Medicure Pharma and the rest of the world by 
Irokocardio International SARL under the brand name Aggrastat as a parenteral solution for 
intravenous administration in dosages of forms 5 mg and 12.5 mg. Tirofiban is a non-
peptidic tyrosine derivative that mimics the RGD motif found on the ligands of GP IIb/IIIa. 
Indications, dosage, and side effects 
Tirofiban is administered intravenously with an initial dose of 0.4 µg/kg/min for the first 30 
minutes, followed by a maintenance dose of 0.1 µg /kg/min as a constant IV infusion for 12-
24 hours following PCI. Tirofiban, in combination with aspirin and heparin, is indicated in 
the treatment of patients with acute coronary syndromes (i.e., unstable angina or acute MI), 
including those who may be undergo subsequent percutaneous coronary intervention, to 
reduce the occurrence of further ischemic damage, new myocardial infarction, and 
mortality. 
Tirofiban has a fast onset and short duration of action, with coagulation parameters 
returning to normal within 4-8 hours after intravenous infusion is stopped. 
The major side effect of tirofiban seen in clinical trials was bleeding, both locally and 
systemically, with major bleeding occurring in 1.4% of patients and minor bleeding in 
10.5%. About 4.0% of patients needed a transfusion to stop intractable bleeding and to 
improve anemia secondary to it. Thrombocytopenia was seen in patients given tirofiban and 
heparin at a rate of about 1.5%, compared to only 0.8% in those receiving heparin alone. This 
side effect was usually reversible within a few days. Positive fecal and urine hemoglobin 
tests were also seen. After the drug entered the market, there have been reports of 
intracranial and retroperitoneal bleeding, pulmonary hemorrhage, spinal-epidural 
hematoma, and hypersensitivity reactions including acute anaphylaxis. Fatal bleedings have 
been rarely reported. 
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3.4.3 Eptifibatide (Integrilin
®
) 
 
 
Eptifibatide is a cyclic heptapeptide that binds GP IIb/IIIa because it contains the KGD 
motif. It is manufactured by Millennium Pharmaceuticals and co-promoted by Schering-
Plough/Essex. Eptifibatide is supplied as a sterile solution in 10-mL vials containing 20 mg 
of the drug, and 100-mL vials containing either 75 mg or 200 mg of eptifibatide. 
Indications, Dosage, and Side Effects 
The recommended adult dosage of eptifibatide in patients with acute coronary syndrome 
that have normal renal function is an intravenous bolus of 180 µg/kg as soon as possible 
following diagnosis, followed by a continuous infusion of 2.0 µg/kg/min for up to 72 hours 
until hospital discharge or initiation of coronary artery bypass graft (CABG) surgery. For 
patients who are to undergo a percutaneous coronary intervention (PCI) while receiving 
eptifibatide, the infusion should be continued up to hospital discharge, or for up to 18 to 24 
hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy. 
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (i.e., death and/or 
myocardial infarction) in patients with unstable angina or non-ST-segment elevation (i.e., 
non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary 
syndromes) both in patients who are to receive non surgery (conservative) medical 
treatment and those undergoing percutaneous coronary intervention (PCI). The drug is 
always applied together with aspirin or clopidogrel and (low molecular weight or 
unfractionated) heparin. 
The side effects of eptifibatide are very similar to those of abciximab. 
4. Ongoing trials of antiplatelet therapy 
According to the International Committee of Medical Journal Editors (ICMJE): 
“Any research study that prospectively assigns human participants or groups of humans to 
one or more health-related interventions to evaluate the effects on health outcomes.” 
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Over the past ten years, government agencies and the IMCJE have issued laws and 
directives on the subject of trial registration. All parties have consistently agreed that the 
purpose of trial registration is to promote the public good by ensuring that the existence and 
design of clinically directive trials are publicly available. The registration effort began with the 
development of a publicly available website, ClinicalTrials.gov, which is a service of the NIH, 
developed by the National Library of Congress. 
In 1997, the FDA/NIH began requiring registration for only a limited number of trials. In 
September, 2007, the Food and Drug Amendments Act (Title VIII. Sec. 801) significantly 
expanded the scope of clinical trials that must be registered. Penalties for failing to register 
“applicable trials” may include civil monetary penalties. 
In 2004, the International Committee of Medical Journal Editors (ICMJE) defined trials that 
must be registered in order to be considered for publication in journals that adhere to ICMJE 
standards. In 2007 the ICMJE expanded the definition of trials that must be registered. 
Scores of journals (not limited to medical journals) have adopted the registration policy. 
The best way to obtain information about clinical trials in platelet activation in ischemic 
heart disease is by accessing two renowned sources: 
http://clinicaltrials.gov 
http://www.clinicaltrialresults.org/ 
Clinicaltrials.gov is a site organized by US government and their webpage states: 
“ClinicalTrials.gov offers up-to-date information for locating federally and privately 
supported clinical trials for a wide range of diseases and conditions. A clinical trial (also 
clinical research) is a research study in human volunteers to answer specific health 
questions.” 
ClinicalTrials.gov currently contains 112,970 trials sponsored by the National Institutes of 
Health, other federal agencies, and private industry. Studies listed in the database are 
conducted in all 50 States and in 175 countries. ClinicalTrials.gov receives over 50 million 
page views per month and 65,000 visitors daily. 
The U.S. National Institutes of Health (NIH), through its National Library of Medicine 
(NLM), has developed this site in collaboration with the Food and Drug Administration 
(FDA), as a result of the FDA Modernization Act, which was passed into law in November 
1997. See the FDA document - Guidance for Industry: Information Program on Clinical 
Trials for Serious or Life-Threatening Diseases and Conditions (March 2002). 
This site allows for selection of all important characteristics of clinical trial to be displayed. 
We can choose any combination of next characteristics: condition, intervention, sponsor, 
gender, age group, phase, number enrolled, funded by, study type, study design, NCT ID, 
other IDs, first received date, start date, completion date, last updated date, last verified 
date, acronym, primary completion date, and outcome measure. 
The second site, http://www.clinicaltrialresults.org/, can be used as excellent source of 
slides, movies, reports, and other useful information about clinical trials. The ‘cardiology’ 
section contains divisions into subspecialty news, with listing about: acute coronary 
syndromes, angina, anticoagulants, antiplatelet agents, antithrombins, congestive heart 
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failure, electrophysiology, imaging, interventional cardiology, prevention, and patient 
resources. Since access to these sources is in the public domain, we decided not to cite 
individual trials by other sources although we went deeper and extracted information from 
from individual trials. We advise our readers to visit these two sites frequently. 
A reasonably informative overview of ongoing trials of antiplatelet therapy is supposed to 
list name and registry number for trial, to describe study population, specify primary end 
point, and define study arms. This data is presented in table 4.1 
Clinical Trial (Registry 
No.) 
Study Population Primary End Point Study Arms 
ACCOAST (NCT01015287)
4,100 patients with 
NSTEMI planned 
to undergo PCI 
CV death, MI, stroke, 
urgent revascularization, 
or GP IIb/IIIa inhibitor 
bailout at 7 days 
Randomized to pre-treatment 
with prasugrel (30 mg at time 
of diagnosis with additional 
30 mg atPCI) vs. prasugrel (60 
mg) at PCI. Maintenance 
therapy in both arms will be 
10 mg daily with dose 
reduction to 5 mg in patients 
>75 yrs and body weight <60 
kg 
ARCTIC (NCT00827411)
2,500 patients 
undergoing 
elective PCI with 
DES 
 
Death, MI, stroke, urgent 
coronary 
revascularization, or stent 
thrombosis assessed at 1 
yr; death, MI, stroke, 
urgent coronary 
revascularization, or stent 
thrombosis at 6–18 
months after second 
randomization 
Initial randomization to 
tailored antiplatelet therapy 
with VerifyNow P2Y12 vs. 
standard dual antiplatelet 
therapy. Subsequent 
randomization after 12 
months of patients who 
remain eventfree to 
discontinuation of antiplatelet 
therapy or continuation of 
therapy 
DANTE Trial 
(NCT00774475) 
442 patients with 
NSTE-ACS 
undergoing PCI 
with stent 
implantation 
found to have 
high residual 
platelet reactivity 
with the 
VerifyNow P2Y12
CV death, MI, or target 
vessel revascularization at 
6 months and 1 yr 
Randomized to 75 mg of 
clopidogrel or 150 mg of 
clopidogrel 
DAPT (NCT00977938) 
20,645 subjects 
undergoing PCI 
CV death, MI, and stroke 
at 33 months; stent 
thrombosis at 33 months
Subjects in the overall cohort 
who are free from death, MI, 
stroke, repeat 
revascularization, stent 
thrombosis, or major bleeding 
at 12 months will be 
randomized to 18 additional 
months of dual antiplatelet 
therapy or aspirin and placebo 
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Clinical Trial (Registry 
No.) 
Study Population Primary End Point Study Arms 
GRAVITAS 
(NCT00645918) 
2,783 subjects after 
DES placement for 
stable CAD or 
NSTE-ACS will 
have platelet 
function testing 
done with 
VerifyNow P2Y12
CV death, MI, and 
definite/ probable stent 
thrombosis at 6 months 
Patients with high residual 
platelet reactivity will be 
randomized to receive 
standard-dose clopidogrel (75 
mg daily) or high-dose 
clopidogrel (600 mg load, 150 
mg daily). A random sample 
of patients without high 
residual platelet reactivity will 
also be enrolled and will 
receive 75 mg of clopidogrel 
daily 
INNOVATE-PCI 
(NCT00751231) 
Phase II trial in 
800 patients 
undergoing 
elective PCI 
No pre-specified primary 
end point 
Randomized to clopidogrel 
(300/600 mg load, followed by 
75 mg daily) or elinogrel (80 
mg IV bolus administered 
before PCI, followed by twice 
daily dosing of oral 50 mg, 100 
mg, or 150 mg) 
LANCELOT 201 
(NCT00312052) 
Phase II trial of 
600 patients with 
CAD 
Safety and tolerability (6 
months) 
Randomized to E5555 (50 mg, 
100 mg, or 200 mg daily) or 
placebo 
LANCELOT 202 
(NCT00548587) 
Phase II trial of 
600 patients with 
CAD 
Safety and tolerability (12 
weeks) 
Randomized to E5555 (50 mg, 
100 mg, or 200 mg daily) or 
placebo 
TRA-CER (NCT00527943)
12,500 subjects 
with ACS 
CV death, MI, stroke, 
recurrent ischemia with 
repeat hospital stay, and 
urgent coronary 
revascularization at end 
of study 
Randomized to SCH 530348 
(40 mg loading dose, 2.5 mg 
daily) vs. placebo 
TRA-2P-TIMI 50 
(NCT00526474) 
26,450 patients 
with history of 
CAD, CVA, or 
PAD 
CV death, MI, stroke, and 
urgent coronary 
revascularization at end 
of study 
Randomized to SCH 530348 
(2.5 mg daily) vs. placebo 
TOPAS-1 (NCT00914368)
Phase II trial of 
450 patients who 
have either had or 
not had stent 
thrombosis or MI 
within 6 months 
of PCI while on 
dual antiplatelet 
therapy 
Establish VerifyNow 
P2Y12 (PRU) and VASP 
(PRI, %) cutoff level of 
platelet inhibition in 
patients with and without 
clinical events. 
All subjects will undergo 
platelet function testing with 
both VerifyNow P2Y12 and 
VASP assays 
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Clinical Trial (Registry 
No.) 
Study Population Primary End Point Study Arms 
TRIGGER-PCI 
(NCT00910299) 
2,150 subjects with 
high residual 
platelet reactivity 
with the 
VerifyNow P2Y12 
after elective PCI 
with DES 
CV death or MI at 6 
months 
Randomized to prasugrel (60 
mg load, 10 mg daily) vs. 
clopidogrel (75 mg daily) 
TRILOGY-ACS 
(NCT00699998) 
10,300 patients 
with NSTE-ACS 
being initially 
medically 
managed 
CV death, MI, or stroke at 
end of study 
Randomized to prasugrel  
(30 mg load ifadministered, 
followed by 5 mg or 10 mg 
maintenance) or  
clopidogrel (300 mg load if 
administered, followed  
by 75 mg daily) 
Table 4.1 
5. Abbreviations 
ACCOAST: Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation 
Myocardial Infarction Trial 
ACS: acute coronary syndrome 
ARCTIC: Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a 
Common Antiplatelet Treatment for DES Implantation, and Interruption Versus 
Continuation of Double Antiplatelet Therapy Trial 
ARMYDA: Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty 
CIPAMI: Clopidogrel Administered Prehospital to Improve Primary PCI in Patients with 
Acute Myocardial Infarction 
CAD: coronary artery disease 
CLARITY-TIMI: Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in 
Myocardial Infarction 
CREDO: Clopidogrel for the Reduction of Events During Observation 
CURE: Clopidogrel in Unstable Angina to Prevent Recurrent Events 
CURRENT/OASIS: Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent 
Events/Optimal Antiplatelet Strategy for Interventions 
CV: cardiovascular 
CVA: cerebrovascular accident 
DANTE: Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition 
DAPT: Dual Antiplatelet Therapy 
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DES: drug-eluting stents 
GP IIb/IIIa: glycoprotein IIb/IIa 
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay—Impact On Thrombosis 
And Safety 
INNOVATE-PCI: A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous 
and Oral P2Y12 Inhibitor, in Non-Urgent PCI 
LANCELOT 201: Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular 
Inflammation in Subjects With Coronary Artery Disease 
LANCELOT 202: Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular 
Inflammation in Subjects With Acute Coronary Syndrome 
MI: myocardial infarction 
NSTE-ACS: non–ST-segment elevation acute coronary syndrome 
NSTEMI: non–ST-segment elevation myocardial infarction 
PAD: peripheral artery disease 
PCI: percutaneous coronary intervention 
PRI: platelet reactivity index 
PRINCIPLE: Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation 
and Aggregation 
PRU: platelet reactivity unit 
STEMI: ST-segment elevation myocardial infarction 
TIMI: Thrombolysis In Myocardial Infarction 
TOPAS-1: Tailoring Of Platelet Inhibition to Avoid Stent Thrombosis 
TRA-CER: Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke 
in Patients With Acute Coronary Syndrome 
TRA-2P-TIMI 50: Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and 
Stroke in Patients With Atherosclerosis 
TRIGGER-PCI: Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement 
on Clopidogrel to Guide Alternative Therapy With Prasugrel 
TRILOGY-ACS: Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome 
Subjects 
TRITON: Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet 
Inhibition with Prasugrel 
VASP: Vasodilator-stimulated phosphorprotein 
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